We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood-Based Control Monitors Immunosuppressant Drug Test Procedures

By Labmedica staff writers
Posted on 17 Jan 2008
A whole blood immunosuppressant control was developed for use as an assayed quality control material to monitor the precision of immunosuppressant drug test procedures in the clinical laboratory from low to very high concentrations. More...


Immunosuppressant drugs are typically used in transplant therapy to help minimize organ rejection. They are also to treat severe skin disorders such as psoriasis and other diseases such as rheumatoid arthritis, Crohn's disease (chronic inflammation of the digestive tract), and patchy hair loss (alopecia areata). Some of these conditions are autoimmune diseases, indicating that the immune system is acting against the body itself.

The new third party, human blood-based control, called Lyphocheck, offers controls for five different immunosuppressive drugs including cyclosporine, tacrolimus, and sirolimus. It can be used with immunoassay or chromatographic techniques.

Lyphocheck was developed by Bio-Rad Laboratories (Hercules, CA, USA), a manufacturer and distributor of clinical diagnostic and life science products. Being a whole blood-based material, Lyphocheck can be processed in the same manner as patient samples, ensuring quality on an ongoing basis.

The Unity Interlaboratory Program and the Unity Real Time, an expert data management software system designed to improve the effectiveness of quality control processes, are available for use with Lyphochek.


Related Links:
Bio-Rad Laboratories

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Hematology Consumables
Bioblood Devices
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.